Sigyn Therapeutics, Inc. (SIGY)

SEC fundamentals · as filed in 10-Q FY2025, period ended Sep 30, 2025 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$135,571
Stockholders' Equity
-$5.9M
Cash & Equivalents
$85,571
Long-Term Debt
$3.5M

as filed in 10-Q FY2025, period ended Sep 30, 2025 · View filings on EDGAR ↗

In its 10-Q for the period ended Sep 30, 2025, Sigyn Therapeutics, Inc. reported net income of -$578,503 and total assets of $135,571. Every figure below is taken directly from Sigyn Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2015–FY2019 · as reported

$143,322-$2.1M-$4.3M
FY2015FY2016FY2017FY2018FY2019
Revenue$143,322Net income-$3.1M
FY2015 revenue
$29,207
FY2019 revenue
$143,322

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2024—-$3.3M
FY2023—-$4.1M
FY2022—-$2.9M
FY2021—-$3.0M
FY2020—-$1.3M
FY2019$143,322-$3.1M
FY2018$28,348-$2.6M
FY2017$38,434-$4.3M
FY2015$29,207-$2.7M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
NT 10-KMar 31, 2026on EDGAR ↗
8-KFeb 20, 2026on EDGAR ↗
10-QNov 14, 2025on EDGAR ↗
10-QSep 5, 2025on EDGAR ↗
8-KAug 15, 2025on EDGAR ↗
10-QMay 20, 2025on EDGAR ↗
10-KApr 15, 2025on EDGAR ↗
8-KMar 7, 2025on EDGAR ↗
8-KJan 16, 2025on EDGAR ↗
8-KJan 6, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Sep 30, 2025 · 10-Q

Total Assets$135,571source ↗
Stockholders’ Equity-$5.9Msource ↗
Cash & Equivalents$85,571source ↗
Long-Term Debt$3.5Msource ↗

Income Statement

10-Q (quarterly) · period ended Sep 30, 2025

Revenue—source ↗
Net Income-$578,503source ↗
Operating Income-$386,529source ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$29,681source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Sep 30, 2025

EPS (diluted)$-0.36source ↗
EPS (basic)$-0.36source ↗
Shares Outstanding1.6Msource ↗
Cash from Operations-$199,326source ↗
Cash from Financing$284,438source ↗
Cash from Investing—source ↗

Restatement history

Point-in-time

6 of 242 annual fact-keys were materially restated between filings: what Sigyn Therapeutics, Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches SIGY’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/SIGY

MCP tool: get_sec_fundamentals ticker=SIGY

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/SIGY/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=SIGY as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/SIGY/history

MCP tool: get_fundamentals_history ticker=SIGY

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/SIGY

MCP tool: get_financial_health ticker=SIGY

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.